AUS
NZ
UK
CA
USA
IND
Highlights:
- HEALWELL AI achieves record revenue and gross profit, driven by AI-enabled healthcare solutions.
- Company expands its footprint with key acquisitions, BioPharma and VeroSource, enhancing pharma partnerships.
- HEALWELL on track to surpass $100 million in revenue and achieve profitability by 2025.
HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF), a healthcare technology company at the forefront of AI and data science for preventative care, has announced impressive financial results for the quarter ended September 30, 2024. The company delivered record revenue and gross profit, fueled by the successful commercialization of its AI and data science business units and transformative acquisitions.
For the quarter, HEALWELL reported substantial growth across key financial metrics, underscoring its expanding role in the healthcare technology space. The company attributed its record performance to the acceleration of its AI-powered solutions, which are increasingly being adopted in both the public and private healthcare sectors.
Dr. Alexander Dobranowski, CEO of HEALWELL, remarked, "During the quarter, we delivered record revenue and gross profit, attributable to the growth in commercialization of our AI and data science business units and our recent acquisitions of BioPharma and VeroSource. These acquisitions were transformational for our business, substantially bolstering our revenues and bringing new key relationships with both public and private sector customers."
HEALWELL’s acquisitions of BioPharma and VeroSource significantly enhance the company’s capabilities, particularly in the pharmaceutical space. BioPharma, a leading player in clinical trial recruitment, and VeroSource, known for its expertise in pharmaceutical data solutions, give HEALWELL the tools to support the entire healthcare pathway—from early disease detection and AI-driven diagnostics to patient placement in clinical trials and the generation of post-trial insights.
These acquisitions have positioned HEALWELL as an "end-to-end pharma partner," able to work across the full continuum of patient care. This expanded capacity strengthens HEALWELL’s ability to help healthcare providers and pharmaceutical companies accelerate the patient care pathway, improve clinical trial efficiency, and harness AI to enhance value-based care initiatives.
"We are now a larger, more robust company, able to participate in the entire healthcare pathway—from early detection of disease using AI to placing qualified patients in clinical trials and generating valuable post-trial insights," Dr. Dobranowski added.
HEALWELL’s AI-enabled patient and disease identification capabilities have been a key driver of its success, winning contracts with top global pharmaceutical companies. As the healthcare sector increasingly turns to AI for preventative care, HEALWELL’s solutions are gaining traction, particularly in the areas of population health management and data interoperability.
The company also reported notable progress in its software divisions, with several key public government contracts won during the quarter. These contracts highlight the growing demand for HEALWELL’s AI-powered healthcare solutions, particularly in the realm of large-scale, data-driven healthcare management.
"We are seeing accelerating commercialization of our solutions across both the public and private sectors, and these wins reflect the growing demand for our AI and healthcare offerings," Dr. Dobranowski noted. "With this momentum, we are confident in our ability to continue driving revenue growth and executing on our long-term vision for the Company."
Looking ahead, HEALWELL is strategically positioned for substantial growth, with its robust acquisition pipeline and strong cash reserves. The company anticipates further announcements in the coming months that will demonstrate its progress toward exceeding a $100 million revenue run rate and achieving profitability on an adjusted EBITDA basis in 2025.
Anthony Lam, HEALWELL’s Chief Financial Officer, stated, "Our strategic initiatives over the next few months will lead to further announcements that will demonstrate our march to a revenue run rate that exceeds $100 million and puts us on track to achieve profitability on an Adjusted EBITDA basis in 2025."
The company’s growth is also reflected in its expanding list of partnerships. During the quarter, HEALWELL secured five new Master Service Agreements (MSAs), bringing the total number of life sciences MSAs to 27. These MSAs provide a steady stream of revenue from pharmaceutical partners and reflect the increasing demand for HEALWELL’s AI and data science capabilities in the healthcare sector.
With a growing customer base and a clear path to profitability, HEALWELL is well-positioned to continue its growth trajectory and solidify its position as a leader in AI-driven healthcare solutions.
